Description | This product is a human monoclonal antibody against Chikungunya virus (CHIKV) with neutralizing activity (IC50 = 100 ng/ml). The mAb specifically binds to an epitope located in an antigenic site of CHIKV envelope proteins. |
Clonality | Monoclonal |
Host Species | Human |
Target Species | Chikungunya virus (CHIKV) |
Isotype | IgG1 |
Expression Species | HEK293F or CHO |
Conjugation | None |
Purity | >95%, determined by SDS-PAGE and SEC-HPLC |
Endotoxin | <1 EU/mg |
Purification | Protein A affinity purified |
Sterility | 0.2 μM filtered |
Formulation | PBS, pH 7.4 |
Preservation | No preservatives |
Stabilizer | No stabilizers |
Storage | Store at 4°C within a week. For longer storage, aliquot and store at -20°C. |
Application | WB; IF; Neut |
Application Notes | The capacity of the purified recombinant antibodies (rec8B10F8 and rec5F10F175E2) to neutralize Chikungunya virus infection in vitro was analyzed by a neutralization test in 96-wells plates. 4000 plaque forming units (PFU) of Chikungunya virus (A226 and A226V strains, respectively) were incubated for 1 hour at 37°C. with 1 μg of recombinant antibody. The mixtures were then added for 1.5 hours to 40,000 HEK 293T cells. Cells were extensively washed and fixed after 24 hours infection. The infection of Chikungunya virus was assessed by incubating the cells for 1 hour with 100 μl of PBS-1/200 anti-Chikungunya virus human plasma as a primary antibody, followed by an anti-human IgG mouse antibody conjugated to Alexa-488 at 2 μg/ml as a secondary antibody. Fluorescence was analyzed under a fluorescent microscope. |
ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
WB | Western Blot Protocol |
FC | Flow Cytometry Protocol |
Target | CHIKV |
Alternative Name | Chikungunya Virus |
Research Area | Infectious Disease |